- Home
- TARS
as of 12-26-2025 3:44pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 2.8B | IPO Year: | 2020 |
| Target Price: | $76.56 | AVG Volume (30 days): | 514.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.51 - $85.25 | Next Earning Date: | 11-04-2025 |
| Revenue: | $366,100,000 | Revenue Growth: | 182.44% |
| Revenue Growth (this year): | 147.24% | Revenue Growth (next year): | 53.11% |
AI-Powered TARS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)
Chief Human Resources Officer
Avg Cost/Share
$80.10
Shares
7,397
Total Value
$592,499.70
Owned After
38,958
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$79.50
Shares
2,078
Total Value
$165,201.00
Owned After
21,941
SEC Form 4
Director
Avg Cost/Share
$81.43
Shares
22,946
Total Value
$1,864,677.82
Owned After
4,766
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Dec 16, 2025 | Sell | $80.10 | 7,397 | $592,499.70 | 38,958 | |
| Lin Elizabeth Yeu | TARS | Chief Medical Officer | Dec 16, 2025 | Sell | $79.50 | 2,078 | $165,201.00 | 21,941 | |
| LINK WILLIAM J PHD | TARS | Director | Dec 15, 2025 | Sell | $81.43 | 22,946 | $1,864,677.82 | 4,766 |
Compare TARS vs Leading Stocks
See how TARS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.